199 related articles for article (PubMed ID: 22320327)
1. Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.
Liu L; Norman MH; Lee M; Xi N; Siegmund A; Boezio AA; Booker S; Choquette D; D'Angelo ND; Germain J; Yang K; Yang Y; Zhang Y; Bellon SF; Whittington DA; Harmange JC; Dominguez C; Kim TS; Dussault I
J Med Chem; 2012 Mar; 55(5):1868-97. PubMed ID: 22320327
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.
Norman MH; Liu L; Lee M; Xi N; Fellows I; D'Angelo ND; Dominguez C; Rex K; Bellon SF; Kim TS; Dussault I
J Med Chem; 2012 Mar; 55(5):1858-67. PubMed ID: 22320343
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).
Liu L; Siegmund A; Xi N; Kaplan-Lefko P; Rex K; Chen A; Lin J; Moriguchi J; Berry L; Huang L; Teffera Y; Yang Y; Zhang Y; Bellon SF; Lee M; Shimanovich R; Bak A; Dominguez C; Norman MH; Harmange JC; Dussault I; Kim TS
J Med Chem; 2008 Jul; 51(13):3688-91. PubMed ID: 18553959
[TBL] [Abstract][Full Text] [Related]
4. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
Schroeder GM; An Y; Cai ZW; Chen XT; Clark C; Cornelius LA; Dai J; Gullo-Brown J; Gupta A; Henley B; Hunt JT; Jeyaseelan R; Kamath A; Kim K; Lippy J; Lombardo LJ; Manne V; Oppenheimer S; Sack JS; Schmidt RJ; Shen G; Stefanski K; Tokarski JS; Trainor GL; Wautlet BS; Wei D; Williams DK; Zhang Y; Zhang Y; Fargnoli J; Borzilleri RM
J Med Chem; 2009 Mar; 52(5):1251-4. PubMed ID: 19260711
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
[TBL] [Abstract][Full Text] [Related]
7. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.
Nakagawa T; Tohyama O; Yamaguchi A; Matsushima T; Takahashi K; Funasaka S; Shirotori S; Asada M; Obaishi H
Cancer Sci; 2010 Jan; 101(1):210-5. PubMed ID: 19832844
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of highly selective pyridone-based class II MET inhibitors.
She N; Zhuo L; Jiang W; Zhu X; Wang J; Ming Z; Zhao X; Cong X; Huang W
Bioorg Med Chem Lett; 2014 Aug; 24(15):3351-5. PubMed ID: 24951334
[TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities.
Kim KS; Zhang L; Schmidt R; Cai ZW; Wei D; Williams DK; Lombardo LJ; Trainor GL; Xie D; Zhang Y; An Y; Sack JS; Tokarski JS; Darienzo C; Kamath A; Marathe P; Zhang Y; Lippy J; Jeyaseelan R; Wautlet B; Henley B; Gullo-Brown J; Manne V; Hunt JT; Fargnoli J; Borzilleri RM
J Med Chem; 2008 Sep; 51(17):5330-41. PubMed ID: 18690676
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
12. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
Cui JJ; Tran-Dubé M; Shen H; Nambu M; Kung PP; Pairish M; Jia L; Meng J; Funk L; Botrous I; McTigue M; Grodsky N; Ryan K; Padrique E; Alton G; Timofeevski S; Yamazaki S; Li Q; Zou H; Christensen J; Mroczkowski B; Bender S; Kania RS; Edwards MP
J Med Chem; 2011 Sep; 54(18):6342-63. PubMed ID: 21812414
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors.
Lee J; Han SY; Jung H; Yang J; Choi JW; Chae CH; Park CH; Choi SU; Lee K; Ha JD; Lee CO; Ryu JW; Kim HR; Koh JS; Cho SY
Bioorg Med Chem Lett; 2012 Jun; 22(12):4044-8. PubMed ID: 22579487
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.
Bode CM; Boezio AA; Albrecht BK; Bellon SF; Berry L; Broome MA; Choquette D; Dussault I; Lewis RT; Lin MH; Rex K; Whittington DA; Yang Y; Harmange JC
Bioorg Med Chem Lett; 2012 Jun; 22(12):4089-93. PubMed ID: 22595176
[TBL] [Abstract][Full Text] [Related]
16. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
Tripathy R; Ghose A; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Aimone LD; Herman JL; Mallamo JP
Bioorg Med Chem Lett; 2007 Mar; 17(6):1793-8. PubMed ID: 17239587
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
18. Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis.
Tripathy R; Reiboldt A; Messina PA; Iqbal M; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Robinson C; Chang H; Ruggeri BA; Mallamo JP
Bioorg Med Chem Lett; 2006 Apr; 16(8):2158-62. PubMed ID: 16460933
[TBL] [Abstract][Full Text] [Related]
19. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.
Prime ME; Courtney SM; Brookfield FA; Marston RW; Walker V; Warne J; Boyd AE; Kairies NA; von der Saal W; Limberg A; Georges G; Engh RA; Goller B; Rueger P; Rueth M
J Med Chem; 2011 Jan; 54(1):312-9. PubMed ID: 21128645
[TBL] [Abstract][Full Text] [Related]
20. Identification of inhibitors of protein kinase B using fragment-based lead discovery.
Saxty G; Woodhead SJ; Berdini V; Davies TG; Verdonk ML; Wyatt PG; Boyle RG; Barford D; Downham R; Garrett MD; Carr RA
J Med Chem; 2007 May; 50(10):2293-6. PubMed ID: 17451234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]